In early 2021, individual investors and institutions hurled money at Moderna stock as if future growth were unlimited.
Investor's Business Daily on MSN8d
Why Moderna Stock Has Surged 15% This Week Despite Mixed NewsModerna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...
Before that, Moderna (NYSE: MRNA) had filed a patent infringement lawsuit against Pfizer and BioNTech in federal court in Massachusetts in 2022. That lawsuit has been on hold waiting for the ...
Zacks Investment Research on MSN9d
Here's Why Moderna Stock Soared 16% on WednesdayShares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on ...
The Düsseldorf Regional Court has ordered Pfizer and its German partner BioNTech to pay damages for the use of Moderna’s ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
DUESSELDORF, Germany (Reuters) -A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 ...
MODERNA (MRNA, Financial) secured a major legal win in its COVID-19 vaccine patent dispute with Pfizer (PFE, Financial) and ...
Pfizer and BioNTech have convinced a U.S. Patent Office tribunal that two patents Moderna accused Pfizer-BioNtech of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback